Siu, Ho Wai Derrick http://orcid.org/0000-0002-2219-2459
Tebbutt, Niall
Chantrill, Lorraine
Karapetis, Chris
Steer, Christopher
Wilson, Kate
Espinoza, David
Bailey, Lisa
Yip, Sonia
Cuff, Jeff
Pavlakis, Nick
Thavaneswaran, Subotheni
Briscoe, Karen
Srivastav, Ratnesh
Shannon, Jennifer
Segelov, Eva
Tie, Jeannie
Caird, Susan
Francesconi, Alessandra
Price, Timothy
Wuttke, Melanie
Ladwa, Rahul
Sjoquist, Katrin
Burge, Matthew
Funding for this research was provided by:
AGITG Innovation Grant
Amgen (20149129)
Article History
Received: 21 December 2020
Accepted: 19 July 2021
First Online: 18 August 2021
Declarations
:
: The trial was approved by the Ethics Review Committee, Sydney Local Health District Research Ethics and Governance Office, Royal Prince Alfred Hospital, New South Wales (Approval date: 6/9/2017, Ethics approval number X17–0248), and by local committees of the participating centres. All participants must provide written informed consent to the study procedures before enrolment in the study.<b>Protocol version identifier and date</b>: v2.0, 12th April 2019.
: Not applicable. No data reported.
: A potential competing interest is the provision of study drug panitumumab by AMGEN. The authors declare that they have no competing interests.